SynthesisFrontiers in medicine2026
Comparing the effectiveness of various cumulative doses of cisplatin in treating locally advanced nasopharyngeal cancer during the period of intensity-modulated radiotherapy: a meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In the age of intensity-modulated radiotherapy (IMRT), the best cumulative cisplatin dose (CCD) for concurrent chemoradiotherapy for locally advanced nasopharyngeal cancer (LA-NPC) is still up for debate. In order to guide clinical dose decisions, this meta-analysis sought to examine the effects of various CCD on survival outcomes. Methods: A thorough search was conducted in PubMed, Embase, Web of Science, and Cochrane Library through December 2025. Randomized controlled trials or observational studies comparing CCD thresholds (≥200 mg/m Results: Included were 10 retrospective cohort studies with 11,220 individuals. OS displayed a favorable trend approaching statistical significance (HR = 0.65, 95% CI: 0.51-0.82). Moderate heterogeneity was observed (I Conclusion: Higher CCD improves DMFS in LA-NPC patients with IMRT, with a near-significant OS trend. However, this survival benefit must be balanced against increased risks of certain acute and late toxicities associated with higher doses. These findings support risk-adapted dose intensification strategies while emphasizing individualized decision-making that integrates efficacy, toxicity, and patient characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.